Table 1.
Examples of Nanomedicines in Clinical Trials for Pancreatic Cancer Treatment.
| Nanomedicine | Nanoscale platform | Anticancer agent | Clinical phase | Refs. |
|---|---|---|---|---|
| NK-105 | Micelles | Paclitaxel | III | [52, 53] |
| Genexol-PM | Polymeric micelles | Paclitaxel | II/III | [54, 55] |
| EndoTAG-1 | Cationic liposome | Paclitaxel | II | [56-58] |
| Abraxane | Albumin | Paclitaxel | FDA approved | [59-60] |
| NC-6004 | Micelles | Cisplatin | III | [61-62] |
| Lipoplatin | Liposome | Cisplatin | II/III | [63] |
| Lipoxal | Liposome | Oxaliplatin | I | [64] |
| Caelyx/Doxil | Liposome | Doxorubicin | I/II | [65, 66] |
| Onco-TSC | Liposome | Vincristine | I | [67] |
| Rexin-G | Retroviral expression vectors | Phospholipid/ microRNA-122 | II/III | [51, 68] |
| SGT53-01 | Transferrin targeted liposome | p53 gene | I | [69] |
| NanoTherm | SPIO | Aminosilane | I | [70] |
| Cyclosert (CALAA-01) | Cyclodextrin polymer | Anti-RRM2 siRNA | Ia/Ib (terminated) | [71] |
| NK911 | Polymeric micelles | Doxorubicin | II | [72] |
| Atu027 | Liposome | Anti-PKN3 siRNA | Ib/IIa | [73] |
| ONIVYDE | Liposome | Irinotecan | FDA approved | [74] |
| ONYX-015 | Replication-selective Ad5 | E1B-55-kDa deleted adinovirus | I/II | [75, 76] |